By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Provista Diagnostics today announced it has entered into purchase agreements with institutional investors to raise $5 million in a Series A Preferred financing.

The funds will go mainly toward the completion of a confirmatory clinical trial and 510(k) submission to the US Food and Drug Administration of its breast cancer test. The remainder will be used to repay outstanding short-term debt obligations, the Phoenix-based firm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.